391 related articles for article (PubMed ID: 31301015)
1. Sunitinib for Metastatic Renal Cell Carcinoma: A Systematic Review and Meta-Analysis of Real-World and Clinical Trials Data.
Moran M; Nickens D; Adcock K; Bennetts M; Desscan A; Charnley N; Fife K
Target Oncol; 2019 Aug; 14(4):405-416. PubMed ID: 31301015
[TBL] [Abstract][Full Text] [Related]
2. Augmenting the randomized controlled trial with real-world data to aid clinical decision making in metastatic renal cell carcinoma: a systematic review and meta-analysis.
Moran M; Nickens D; Adcock K; Bennetts M; Charnley N; Fife K
Future Oncol; 2019 Dec; 15(34):3987-4001. PubMed ID: 31623465
[No Abstract] [Full Text] [Related]
3. Second line therapy with axitinib after only prior sunitinib in metastatic renal cell cancer: Italian multicenter real world SAX study final results.
Facchini G; Rossetti S; Berretta M; Cavaliere C; Scagliarini S; Vitale MG; Ciccarese C; Di Lorenzo G; Palesandro E; Conteduca V; Basso U; Naglieri E; Farnesi A; Aieta M; Borsellino N; La Torre L; Iovane G; Bonomi L; Gasparro D; Ricevuto E; De Tursi M; De Vivo R; Lo Re G; Grillone F; Marchetti P; De Vita F; Scavelli C; Sini C; Pisconti S; Crispo A; Gebbia V; Maestri A; Galli L; De Giorgi U; Iacovelli R; Buonerba C; Cartenì G; D'Aniello C
J Transl Med; 2019 Aug; 17(1):296. PubMed ID: 31464635
[TBL] [Abstract][Full Text] [Related]
4. Pazopanib has equivalent anti-tumor effectiveness and lower Total costs than Sunitinib for treating metastatic or advanced renal cell carcinoma: a meta-analysis.
Deng H; Huang Y; Hong Z; Yuan X; Cao Z; Wei Y; Zhang W
BMC Cancer; 2019 May; 19(1):489. PubMed ID: 31122210
[TBL] [Abstract][Full Text] [Related]
5. [Comparison of efficacy between sorafenib and sunitinib as first-line therapy for metastatic renal cell carcinoma and analyze prognostic factors for survival].
Cai W; Yuan YC; Li MY; Kong W; Dong BJ; Chen YH; Zhang J; Xue W; Huang YR; Zhou LX; Huang JW
Zhonghua Zhong Liu Za Zhi; 2018 May; 40(5):384-389. PubMed ID: 29860767
[No Abstract] [Full Text] [Related]
6. Sunitinib in Patients With Metastatic Renal Cell Carcinoma: Clinical Outcome According to International Metastatic Renal Cell Carcinoma Database Consortium Risk Group.
Rini BI; Hutson TE; Figlin RA; Lechuga MJ; Valota O; Serfass L; Rosbrook B; Motzer RJ
Clin Genitourin Cancer; 2018 Aug; 16(4):298-304. PubMed ID: 29853320
[TBL] [Abstract][Full Text] [Related]
7. Impact of Clinicopathological Features on Survival in Patients Treated with First-line Immune Checkpoint Inhibitors Plus Tyrosine Kinase Inhibitors for Renal Cell Carcinoma: A Meta-analysis of Randomized Clinical Trials.
Rizzo A; Mollica V; Santoni M; Ricci AD; Rosellini M; Marchetti A; Montironi R; Ardizzoni A; Massari F
Eur Urol Focus; 2022 Mar; 8(2):514-521. PubMed ID: 33714725
[TBL] [Abstract][Full Text] [Related]
8. Tolerability of Alternative Dosing Schedules for Sunitinib: A Systematic Review and Meta-Analysis.
Kang HJ; Lee S
Yonsei Med J; 2020 Oct; 61(10):837-843. PubMed ID: 32975057
[TBL] [Abstract][Full Text] [Related]
9. First-line sunitinib versus pazopanib in metastatic renal cell carcinoma: Results from the International Metastatic Renal Cell Carcinoma Database Consortium.
Ruiz-Morales JM; Swierkowski M; Wells JC; Fraccon AP; Pasini F; Donskov F; Bjarnason GA; Lee JL; Sim HW; Sliwczynsk A; Ptak-Chmielewska A; Teter Z; Beuselinck B; Wood LA; Yuasa T; Pezaro C; Rini BI; Szczylik C; Choueiri TK; Heng DY
Eur J Cancer; 2016 Sep; 65():102-8. PubMed ID: 27487293
[TBL] [Abstract][Full Text] [Related]
10. Use of targeted therapy in patients with metastatic renal cell carcinoma: clinical and economic impact in a Canadian real-life setting.
Nazha S; Tanguay S; Kapoor A; Jewett M; Kollmannsberger C; Wood L; Bjarnason G; Heng D; Soulières D; Reaume N; Basappa N; Lévesque E; Dragomir A
Curr Oncol; 2018 Dec; 25(6):e576-e584. PubMed ID: 30607126
[TBL] [Abstract][Full Text] [Related]
11. Efficacy of sequential therapies with sorafenib-sunitinib versus sunitinib-sorafenib in metastatic renal cell carcinoma: A systematic review and meta-analysis.
Wen T; Xiao H; Luo C; Huang L; Xiong M
Oncotarget; 2017 Mar; 8(12):20441-20451. PubMed ID: 28099901
[TBL] [Abstract][Full Text] [Related]
12. Clinical Effectiveness of Second-line Sunitinib Following Immuno-oncology Therapy in Patients with Metastatic Renal Cell Carcinoma: A Real-world Study.
Wells JC; Dudani S; Gan CL; Stukalin I; Azad AA; Liow E; Donskov F; Yuasa T; Pal SK; De Velasco G; Hansen AR; Beuselinck B; Kollmannsberger CK; Powles T; McGregor BA; Duh MS; Huynh L; Heng DYC
Clin Genitourin Cancer; 2021 Aug; 19(4):354-361. PubMed ID: 33863648
[TBL] [Abstract][Full Text] [Related]
13. Everolimus Versus Sunitinib Prospective Evaluation in Metastatic Non-Clear Cell Renal Cell Carcinoma (ESPN): A Randomized Multicenter Phase 2 Trial.
Tannir NM; Jonasch E; Albiges L; Altinmakas E; Ng CS; Matin SF; Wang X; Qiao W; Dubauskas Lim Z; Tamboli P; Rao P; Sircar K; Karam JA; McDermott DF; Wood CG; Choueiri TK
Eur Urol; 2016 May; 69(5):866-74. PubMed ID: 26626617
[TBL] [Abstract][Full Text] [Related]
14. Third-line sorafenib after sequential therapy with sunitinib and mTOR inhibitors in metastatic renal cell carcinoma.
Di Lorenzo G; Buonerba C; Federico P; Rescigno P; Milella M; Ortega C; Aieta M; D'Aniello C; Longo N; Felici A; Ruggeri EM; Palmieri G; Imbimbo C; Aglietta M; De Placido S; Mirone V
Eur Urol; 2010 Dec; 58(6):906-11. PubMed ID: 20884115
[TBL] [Abstract][Full Text] [Related]
15. Multikinase inhibitors in metastatic renal cell carcinoma: indirect comparison meta-analysis.
Leung HW; Chan AL
Clin Ther; 2011 Jun; 33(6):708-16. PubMed ID: 21704235
[TBL] [Abstract][Full Text] [Related]
16. Comparison of axitinib and sunitinib as first-line therapies for metastatic renal cell carcinoma: a real-world multicenter analysis.
Konishi S; Hatakeyama S; Tanaka T; Ikehata Y; Tanaka T; Fujita N; Ishibashi Y; Yamamoto H; Yoneyama T; Hashimoto Y; Yoshikawa K; Kawaguchi T; Masumori N; Kitamura H; Ohyama C
Med Oncol; 2018 Nov; 36(1):6. PubMed ID: 30474747
[TBL] [Abstract][Full Text] [Related]
17. Cost analysis for different sequential treatment regimens for metastatic renal cell carcinoma in China.
Shi G; Park SH; Ren H; Xue M; Lu X; Dong P; Gao X
J Med Econ; 2018 Dec; 21(12):1150-1158. PubMed ID: 30134758
[TBL] [Abstract][Full Text] [Related]
18. Synergistic Survival: A New Phenomenon Connected to Adverse Events of First-Line Sunitinib Treatment in Advanced Renal Cell Carcinoma.
Nagyiványi K; Budai B; Bíró K; Gyergyay F; Noszek L; Küronya Z; Németh H; Nagy P; Géczi L
Clin Genitourin Cancer; 2016 Aug; 14(4):314-22. PubMed ID: 26774206
[TBL] [Abstract][Full Text] [Related]
19. Hypertension as a prognostic factor in metastatic renal cell carcinoma treated with tyrosine kinase inhibitors: a systematic review and meta-analysis.
Liu Y; Zhou L; Chen Y; Liao B; Ye D; Wang K; Li H
BMC Urol; 2019 Jun; 19(1):49. PubMed ID: 31174518
[TBL] [Abstract][Full Text] [Related]
20. Immune-based combinations for the treatment of metastatic renal cell carcinoma: a meta-analysis of randomised clinical trials.
Massari F; Rizzo A; Mollica V; Rosellini M; Marchetti A; Ardizzoni A; Santoni M
Eur J Cancer; 2021 Sep; 154():120-127. PubMed ID: 34265504
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]